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The lower pregnancy-associated pyrimethamine clearance reported by de Kock et al. 1 would be unusual, as there are few drugs that exhibit this property. We recently re-examined our own published pyrimethamine data from pregnant Papua New Guinean women 4 and those of other relevant studies with apparently disparate findings, and proposed that lactation status could help to explain between-study differences. As we outlined, 4 national breastfeeding rates in the various studies were high (!84%) up to 1 year postpartum at the time. There is evidence (see Supplementary Material) that breast tissue expresses cytochrome P450 (CYP) genes, especially CYP1B1 which codes for a key enzyme involved in the metabolism of pyrimethamine, as identified in vitro using recombinant CYP enzymes. At present, the primary interest in mammary enzymes is related to breast malignancy rather than drug metabolism, but the expression of CYP enzymes can be upregulated during breastfeeding, which may reduce maternal exposure postpartum. It is of interest that in all studies that compared the disposition of pyrimethamine during pregnancy with that after delivery, including the four substudies analyzed by de Kock et al.,
1 the AUC did not return to levels in nonpregnant women in the postpartum period despite variability between studies (see Figure 1 ). This suggests strongly that lactating women are not metabolically equivalent to nonpregnant women in the case of pyrimethamine. The reduced pyrimethamine clearance in pregnancy relative to thatpostpartum, as reported by de Kock et al., 1 does not, therefore, contradict other studies using nonpregnant women as the comparator group that showed increased pyrimethamine clearance and a lower AUC. 3, 4 We conclude that there should be careful selection of an appropriate control group in studies of drug disposition in pregnancy, including consideration of lactation, because the postpartum state may not be equivalent to that in nonpregnant women. 
